Penumbra rises after Q4 results, brokerages turn bullish

Penumbra

19/02/2025 11:58

** Medical equipment maker Penumbra  PEN.N  rise 8.39% to
$293.90 in premarket trading 
    ** Revenue rises 10.8% to $315.52 million from a year
earlier in fourth quarter; analysts expected $311.52 million,
per data compiled by LSEG
    ** "We expect cash generation to scale nicely in the coming
years," analysts at Morgan Stanley say
    ** J.P.Morgan says "with another year of low-to-mid teens
sales growth on tap plus nice margin expansion Penumbra is
delivering good fundamental results"
    ** Of the 19 brokerages covering the stock, at least 14
raised their price targets following the results
    ** Brokerage Canaccord Genuity raises PT to $340, a Wall
Street high, from $323 
    ** Average rating is "buy", with a median PT of $308 - LSEG
    ** As of last close, stock up ~14% this year; stock fell ~6%
in 2024

 (Reporting by Joel Jose in Bengaluru)
 ((joeljose@thomsonreuters.com))